Share
.webp)
.webp)
.webp)
.webp)
Dr. Roland W. Bürli
Scenic Biotech, a pioneer in the development of modifier therapies for severe diseases, has appointed Roland W. Bürli, PhD, as Chief Scientific Officer (CSO).
Dr. Bürli brings more than 25 years of experience in drug discovery and development, with a proven track record of advancing innovative therapeutics from early research through preclinical and clinical stages.
At Scenic, Dr. Bürli will oversee the company’s scientific strategy and guide the advancement of its pipeline of first-in-class modifier therapies targeting neurodegenerative and metabolic diseases. His deep expertise in building and leading R&D organizations, coupled with his successful experience in fundraising and partnership development, will be pivotal in strengthening Scenic’s position as a leader in this emerging therapeutic field.
Dr. Bürli joins Scenic from Codify Therapeutics, where he established the discovery platform following the company’s inception in 2022. Before this, he was Vice President of Drug Discovery at Cerevance, where he built a multidisciplinary team, helped secure Series B financing, and advanced multiple small-molecule programs, including CVN293, which progressed through Phase 1 clinical trials.
Earlier in his career, he held senior scientific positions at AstraZeneca, BioFocus, Amgen, and GeneSoft, contributing to the discovery of candidates in CNS, inflammation, hematology, and infectious diseases.
Dr. Bürli holds a PhD in Organic Chemistry from ETH Zürich and completed postdoctoral research at the California Institute of Technology. He is co-author and co-inventor on more than 135 peer-reviewed publications and patents.
